Two European cell therapy companies have decided to merge in order to create a pipeline of allogeneic cell therapies directed against both solid and blood-borne tumours. The merger will see Sweden-based Immunicum AB take control of DCprime BV of the Netherlands through the issuance of 74 million shares valued at about SEK 600 million (€59 million). DCprime’s majority shareholder, Van Herk Investments BV, will hold approximately 43% of the combined company. Together, the new entity is expected to have funding to support product development into the beginning of 2022.
